Literature DB >> 26599185

Distal Symmetric Polyneuropathy: A Review.

Brian C Callaghan1, Raymond S Price2, Eva L Feldman1.   

Abstract

IMPORTANCE: Peripheral neuropathy is a highly prevalent and morbid condition affecting 2% to 7% of the population. Patients frequently experience pain and are at risk of falls, ulcerations, and amputations. We aimed to review recent diagnostic and therapeutic advances in distal symmetric polyneuropathy, the most common subtype of peripheral neuropathy. OBSERVATIONS: Current evidence supports limited routine laboratory testing in patients with distal symmetric polyneuropathy. Patients without a known cause should undergo a complete blood cell count, comprehensive metabolic panel, vitamin B12 measurement, serum protein electrophoresis with immunofixation, fasting glucose measurement, and glucose tolerance test. The presence of atypical features such as asymmetry, non-length dependence, motor predominance, acute or subacute onset, and prominent autonomic involvement should prompt a consultation with a neurologist or neuromuscular specialist. Electrodiagnostic tests and magnetic resonance imaging of the neuroaxis contribute substantial cost to the diagnostic evaluation, but evidence supporting their use is lacking. Strong evidence supports the use of tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, and voltage-gated calcium channel ligands in the treatment of neuropathic pain. More intensive glucose control substantially reduces the incidence of distal symmetric polyneuropathy in patients with type 1 diabetes but not in those with type 2 diabetes. CONCLUSIONS AND RELEVANCE: The opportunity exists to improve guideline-concordant testing in patients with distal symmetric polyneuropathy. Moreover, the role of electrodiagnostic tests needs to be further defined, and interventions to reduce magnetic resonance imaging use in this population are needed. Even though several efficacious medications exist for neuropathic pain treatment, pain is still underrecognized and undertreated. New disease-modifying medications are needed to prevent and treat peripheral neuropathy, particularly in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26599185      PMCID: PMC5125083          DOI: 10.1001/jama.2015.13611

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  77 in total

1.  Factors associated with falls in older patients with diffuse polyneuropathy.

Authors:  James K Richardson
Journal:  J Am Geriatr Soc       Date:  2002-11       Impact factor: 5.562

2.  Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy.

Authors:  Brian C Callaghan; Kevin A Kerber; Lynda L Lisabeth; Lewis B Morgenstern; Ruth Longoria; Ann Rodgers; Paxton Longwell; Eva L Feldman
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

3.  A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

Authors:  J F Wernicke; Y L Pritchett; D N D'Souza; A Waninger; P Tran; S Iyengar; J Raskin
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

4.  Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study.

Authors:  M L Sands; S M Shetterly; G M Franklin; R F Hamman
Journal:  Diabetes Care       Date:  1997-03       Impact factor: 19.112

5.  A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.

Authors:  Joel Raskin; Yili L Pritchett; Fujun Wang; Deborah N D'Souza; Amy L Waninger; Smriti Iyengar; Joachim F Wernicke
Journal:  Pain Med       Date:  2005 Sep-Oct       Impact factor: 3.750

6.  Incidence of polyneuropathy in Utrecht, the Netherlands.

Authors:  Nora A Visser; Nicolette C Notermans; Rosalie S N Linssen; Leonard H van den Berg; Alexander F J E Vrancken
Journal:  Neurology       Date:  2014-12-12       Impact factor: 9.910

7.  Epidemiology of cervical radiculopathy. A population-based study from Rochester, Minnesota, 1976 through 1990.

Authors:  K Radhakrishnan; W J Litchy; W M O'Fallon; L T Kurland
Journal:  Brain       Date:  1994-04       Impact factor: 13.501

8.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

9.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

10.  Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.

Authors:  Julio Rosenstock; Michael Tuchman; Linda LaMoreaux; Uma Sharma
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

View more
  51 in total

Review 1.  New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism.

Authors:  Stephanie Eid; Kelli M Sas; Steven F Abcouwer; Eva L Feldman; Thomas W Gardner; Subramaniam Pennathur; Patrice E Fort
Journal:  Diabetologia       Date:  2019-07-25       Impact factor: 10.122

2.  Chain length of saturated fatty acids regulates mitochondrial trafficking and function in sensory neurons.

Authors:  Amy E Rumora; Giovanni LoGrasso; Julia A Haidar; Justin J Dolkowski; Stephen I Lentz; Eva L Feldman
Journal:  J Lipid Res       Date:  2018-11-15       Impact factor: 5.922

3.  The Divergent Roles of Dietary Saturated and Monounsaturated Fatty Acids on Nerve Function in Murine Models of Obesity.

Authors:  Amy E Rumora; Giovanni LoGrasso; John M Hayes; Faye E Mendelson; Maegan A Tabbey; Julia A Haidar; Stephen I Lentz; Eva L Feldman
Journal:  J Neurosci       Date:  2019-03-18       Impact factor: 6.167

4.  Activation of TRPM2 and TRPV1 Channels in Dorsal Root Ganglion by NADPH Oxidase and Protein Kinase C Molecular Pathways: a Patch Clamp Study.

Authors:  Mustafa Nazıroğlu
Journal:  J Mol Neurosci       Date:  2017-01-17       Impact factor: 3.444

5.  Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy.

Authors:  Chaoling Dong; E Scott Helton; Ping Zhou; Xuan Ouyang; Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo; Eroboghene E Ubogu
Journal:  Tissue Barriers       Date:  2018-09-05

6.  Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story.

Authors:  Lucy M Hinder; Benjamin J Murdock; Meeyoung Park; Diane E Bender; Phillipe D O'Brien; Amy E Rumora; Junguk Hur; Eva L Feldman
Journal:  Exp Neurol       Date:  2018-03-14       Impact factor: 5.330

7.  Integrating cannabis into clinical cancer care.

Authors:  D I Abrams
Journal:  Curr Oncol       Date:  2016-03-16       Impact factor: 3.677

Review 8.  Neurologic examination in the elderly.

Authors:  Navid Seraji-Bzorgzad; Henry Paulson; Judith Heidebrink
Journal:  Handb Clin Neurol       Date:  2019

9.  Better diagnostic accuracy of neuropathy in obesity: A new challenge for neurologists.

Authors:  Brian C Callaghan; Rong Xia; Evan Reynolds; Mousumi Banerjee; Charles Burant; Amy Rothberg; Rodica Pop-Busui; Emily Villegas-Umana; Eva L Feldman
Journal:  Clin Neurophysiol       Date:  2018-01-16       Impact factor: 3.708

Review 10.  Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.

Authors:  Rick T Dobrowsky
Journal:  Curr Diab Rep       Date:  2016-08       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.